Represents the initial payment made by the entity in accordance with an asset purchase agreement. Amount paid was charged to research and development expense by the entity during the period.

No definition available.

+ Details

Name:	sgyp_AssetPurchaseAgreementInitialPayment
Namespace Prefix:	sgyp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	sgyp_AssetPurchaseAgreementLineItems
Namespace Prefix:	sgyp_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the minimum net sales milestone to be achieved for payment of subsequent milestones under an asset purchase agreement.

+ References

No definition available.

+ Details

Name:	sgyp_AssetPurchaseAgreementMilestoneOfNetSalesMinimum
Namespace Prefix:	sgyp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Carrying amount, as of the balance sheet date, of payments made in advance for research and development costs, which will be charged against earnings within one year or the normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name:	sgyp_PrepaidResearchAndDevelopmentExpense
Namespace Prefix:	sgyp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_ResearchAndDevelopmentAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Research and Development Expense (Details) (USD $)	3 Months Ended	12 Months Ended	98 Months Ended	0 Months Ended	12 Months Ended
Research and Development Expense (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2013	Aug. 17, 2012 Bristol-Myers Squibb Company FV-100	Dec. 31, 2012 Bristol-Myers Squibb Company FV-100
Research and Development Expense
Prepaid research and development costs		$ 900,000	$ 3,600,000
Asset Purchase Agreement
Initial payment in terms of agreement				1,000,000
Milestone of aggregate net sales				125,000,000
Purchased in-process research and development	$ 1,000,000	$ 1,000,000	$ 29,157,000		$ 1,000,000